title: [Radiochemotherapy and simultaneous hormonal therapy of locally advanced prostatic carcinoma].
abstract: OBJECTIVE
  The results of radiotherapy alone in the prostate cancer stage T3-T4 are not satisfactory. We investigated, whether the combination of radio-chemotherapy with hormone therapy, possible most effective therapy in stage III, will be tolerated without serious side effects.
  
  
  METHODS
  Eight patients with prostate cancer T3/T4 were treated with concurrent radio-chemotherapy and hormone therapy. The mean doses in reference point was 61.7 Gy, the single dose was 1.8 Gy. The patients received epirubicin 20 mg/m2 and 5-fluorouracil 800 mg/m2 on day 1 to 5 and 29 to 33 of radiotherapy. The hormone therapy began before the radio-chemotherapy started.
  
  
  RESULTS
  Only the hematological side effects were relevant. Three out of 8 patients had leucopenia grade III and 1 of 8 patients leucopenia grade IV according WHO. Other serious complications could not be observed.
  
  
  CONCLUSIONS
  The concurrent radio-chemotherapy with epirubicin and 5-fluorouracil in the combination with hormone therapy was tolerated well. The effectiveness of this new treatment should be examined prospectively in prostate cancer stage T3-T4.
authors.affiliation: Klinik und Poliklinik für Strahlentherapie, Universität Erlangen-Nürnberg.
authors.forename: V
authors.initials: V
authors.lastname: Strnad
authors.forename: M
authors.initials: M
authors.lastname: Riepl
authors.forename: R
authors.initials: R
authors.lastname: Kühn
authors.forename: R
authors.initials: R
authors.lastname: Sauer
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000150:complications / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001773:Blood Cells / Q000187:drug effects / Q000528:radiation effects; D002296:Carcinosarcoma / Q000097:blood / Q000150:complications / Q000628:therapy*; D003131:Combined Modality Therapy; D006728:Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications / Q000628:therapy*; D011879:Radiotherapy Dosage
chemical_list: D006728:Hormones